These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 15184044)

  • 1. Development of Abeta terminal end-specific antibodies and sensitive ELISA for Abeta variant.
    Horikoshi Y; Sakaguchi G; Becker AG; Gray AJ; Duff K; Aisen PS; Yamaguchi H; Maeda M; Kinoshita N; Matsuoka Y
    Biochem Biophys Res Commun; 2004 Jul; 319(3):733-7. PubMed ID: 15184044
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characterization of Abeta11-40/42 peptide deposition in Alzheimer's disease and young Down's syndrome brains: implication of N-terminally truncated Abeta species in the pathogenesis of Alzheimer's disease.
    Liu K; Solano I; Mann D; Lemere C; Mercken M; Trojanowski JQ; Lee VM
    Acta Neuropathol; 2006 Aug; 112(2):163-74. PubMed ID: 16865398
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Abeta N-terminal-end specific antibody reduced beta-amyloid in Alzheimer-model mice.
    Horikoshi Y; Mori T; Maeda M; Kinoshita N; Sato K; Yamaguchi H
    Biochem Biophys Res Commun; 2004 Dec; 325(2):384-7. PubMed ID: 15530403
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characterisation of two antibodies to oligomeric Abeta and their use in ELISAs on human brain tissue homogenates.
    van Helmond Z; Heesom K; Love S
    J Neurosci Methods; 2009 Jan; 176(2):206-12. PubMed ID: 18824027
    [TBL] [Abstract][Full Text] [Related]  

  • 5. P-glycoprotein efflux and other factors limit brain amyloid beta reduction by beta-site amyloid precursor protein-cleaving enzyme 1 inhibitors in mice.
    Meredith JE; Thompson LA; Toyn JH; Marcin L; Barten DM; Marcinkeviciene J; Kopcho L; Kim Y; Lin A; Guss V; Burton C; Iben L; Polson C; Cantone J; Ford M; Drexler D; Fiedler T; Lentz KA; Grace JE; Kolb J; Corsa J; Pierdomenico M; Jones K; Olson RE; Macor JE; Albright CF
    J Pharmacol Exp Ther; 2008 Aug; 326(2):502-13. PubMed ID: 18499745
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High sensitivity analysis of amyloid-beta peptide composition in amyloid deposits from human and PS2APP mouse brain.
    Güntert A; Döbeli H; Bohrmann B
    Neuroscience; 2006 Dec; 143(2):461-75. PubMed ID: 17008022
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The levels of soluble versus insoluble brain Abeta distinguish Alzheimer's disease from normal and pathologic aging.
    Wang J; Dickson DW; Trojanowski JQ; Lee VM
    Exp Neurol; 1999 Aug; 158(2):328-37. PubMed ID: 10415140
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Abeta43 is more frequent than Abeta40 in amyloid plaque cores from Alzheimer disease brains.
    Welander H; Frånberg J; Graff C; Sundström E; Winblad B; Tjernberg LO
    J Neurochem; 2009 Jul; 110(2):697-706. PubMed ID: 19457079
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Humoral immune response to fibrillar beta-amyloid peptide.
    Miller DL; Currie JR; Mehta PD; Potempska A; Hwang YW; Wegiel J
    Biochemistry; 2003 Oct; 42(40):11682-92. PubMed ID: 14529278
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A novel monoclonal antibody specific for the amino-truncated beta-amyloid Abeta5-40/42 produced from caspase-cleaved amyloid precursor protein.
    Murayama KS; Kametani F; Tabira T; Araki W
    J Neurosci Methods; 2007 Apr; 161(2):244-9. PubMed ID: 17207535
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Amyloid beta protein starting pyroglutamate at position 3 is a major component of the amyloid deposits in the Alzheimer's disease brain.
    Harigaya Y; Saido TC; Eckman CB; Prada CM; Shoji M; Younkin SG
    Biochem Biophys Res Commun; 2000 Sep; 276(2):422-7. PubMed ID: 11027491
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Deposition of mouse amyloid beta in human APP/PS1 double and single AD model transgenic mice.
    van Groen T; Kiliaan AJ; Kadish I
    Neurobiol Dis; 2006 Sep; 23(3):653-62. PubMed ID: 16829076
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dendrimeric Abeta1-15 is an effective immunogen in wildtype and APP-tg mice.
    Seabrook TJ; Thomas K; Jiang L; Bloom J; Spooner E; Maier M; Bitan G; Lemere CA
    Neurobiol Aging; 2007 Jun; 28(6):813-23. PubMed ID: 16725229
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Abeta42 immunization in Alzheimer's disease generates Abeta N-terminal antibodies.
    Lee M; Bard F; Johnson-Wood K; Lee C; Hu K; Griffith SG; Black RS; Schenk D; Seubert P
    Ann Neurol; 2005 Sep; 58(3):430-5. PubMed ID: 16130106
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Direct in vivo intracellular selection of conformation-sensitive antibody domains targeting Alzheimer's amyloid-beta oligomers.
    Meli G; Visintin M; Cannistraci I; Cattaneo A
    J Mol Biol; 2009 Apr; 387(3):584-606. PubMed ID: 19361429
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Plasma antibodies to Abeta40 and Abeta42 in patients with Alzheimer's disease and normal controls.
    Xu W; Kawarabayashi T; Matsubara E; Deguchi K; Murakami T; Harigaya Y; Ikeda M; Amari M; Kuwano R; Abe K; Shoji M
    Brain Res; 2008 Jul; 1219():169-79. PubMed ID: 18534566
    [TBL] [Abstract][Full Text] [Related]  

  • 17. BACE1 inhibition reduces endogenous Abeta and alters APP processing in wild-type mice.
    Nishitomi K; Sakaguchi G; Horikoshi Y; Gray AJ; Maeda M; Hirata-Fukae C; Becker AG; Hosono M; Sakaguchi I; Minami SS; Nakajima Y; Li HF; Takeyama C; Kihara T; Ota A; Wong PC; Aisen PS; Kato A; Kinoshita N; Matsuoka Y
    J Neurochem; 2006 Dec; 99(6):1555-63. PubMed ID: 17083447
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development of a specific ELISA for the quantitative study of amino-terminally truncated beta-amyloid peptides.
    El Mouedden M; Vandermeeren M; Meert T; Mercken M
    J Neurosci Methods; 2005 Jun; 145(1-2):97-105. PubMed ID: 15922029
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dynamics of {beta}-amyloid reductions in brain, cerebrospinal fluid, and plasma of {beta}-amyloid precursor protein transgenic mice treated with a {gamma}-secretase inhibitor.
    Barten DM; Guss VL; Corsa JA; Loo A; Hansel SB; Zheng M; Munoz B; Srinivasan K; Wang B; Robertson BJ; Polson CT; Wang J; Roberts SB; Hendrick JP; Anderson JJ; Loy JK; Denton R; Verdoorn TA; Smith DW; Felsenstein KM
    J Pharmacol Exp Ther; 2005 Feb; 312(2):635-43. PubMed ID: 15452193
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Consequence of Abeta immunization on the vasculature of human Alzheimer's disease brain.
    Boche D; Zotova E; Weller RO; Love S; Neal JW; Pickering RM; Wilkinson D; Holmes C; Nicoll JA
    Brain; 2008 Dec; 131(Pt 12):3299-310. PubMed ID: 18953056
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.